Dual Specificity Protein Phosphatase 1/6 Inhibitor, BCI
The Dual Specificity Protein Phosphatase 1/6 Inhibitor, BCI controls the biological activity of Dual Specificity Protein Phosphatase 1/6. Primarily used for Phosphorylation & Dephosphorylation apps.
A cell-permeable cyclohexylamino-indenone compound that acts as an allosteric inhibitor against substrate binding-induced MAPK phosphatase activity of Dusp1/CL100/HVH1/MKP1/PTPN10 and Dusp6/MKP3/PYST1 (57% and 30% reduction, respectively, of 0.21 and 2.1 µg Erk2-induced OMFP dephosphorylation by 0.21 µg Dusp6) by locking Dusp1 and Dusp6 in their low-activity conformation, while exhibiting little activity toward Cdc25B, DUSP3/VHR, DUSP5, or PTP1B. Shown to effectively enhance cellular Erk phosphorylation in HeLa cells overexpressing human Dusp1 and Dusp6 (EC50 = 11.5 and 12.3 µM, respectively). FGF signaling activation by BCI treatment (5 to 10 µM) during zebrafish embryo development is reported to expand myocardial progenitors population at the expense of other progenitor cell types, resulting in enlarged heart size.
Envase
Packaged under inert gas
Advertencia
Toxicity: Standard Handling (A)
Reconstitución
Following reconstiution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Otras notas
Molina, G., et al. 2009. Nat. Chem. Biol.5, 680.
Información legal
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Idiopathic pulmonary fibrosis (IPF) is a progressive terminal lung disease, and therapies aim to block fibrosis. Fibroblast proliferation is controlled by C/EBP-β, microRNA cluster 17-92 (miR17-92), and Erk1/2 mitogen-activated protein kinase. This study assessed the role of miR17-92 in IPF-fibroblast
Meningiomas are the most common primary intracranial tumor with current classification offering limited therapeutic guidance. Here, we interrogated meningioma enhancer landscapes from 33 tumors to stratify patients based upon prognosis and identify novel meningioma-specific dependencies. Enhancers robustly stratified meningiomas into
Preguntas
Revisiones
★★★★★ Sin puntuación
Filtros activos
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
